

**Amendments to the Claims:** This listing of claims will replace all prior versions, and listings, of claims in the application

Claims 1-54 (cancelled)

55. (**Currently Amended**) An isolated recombinant polypeptide comprising ~~a member selected from the group consisting of:~~

- (a) the amino acid sequence of SEQ ID NO:2, ~~and or,~~
- (b) an immunogenic polypeptide ~~comprising a fragment sequence of at least 15~~ 57 contiguous amino acids having an aligned contiguous segment from amino acid positions 1-47 or amino acid positions 104-276 of SEQ ID NO:2, wherein the immunogenic fragment isolated polypeptide, when administered to a subject as a conjugate with a suitable carrier or in a composition which can include an adjuvant, or conjugated to a suitable carrier, induces is capable of inducing an antibody or T-cell immune response to the polypeptide sequence of that specifically binds to said fragment within SEQ ID NO:2.

56. (Previously Presented) The isolated recombinant polypeptide of claim 55, wherein the polypeptide comprises the amino acid sequence SEQ ID NO:2.

57. (Previously Presented) The isolated recombinant polypeptide of claim 55, wherein the polypeptide consists of the amino acid sequence SEQ ID NO:2.

58. (**Currently Amended**) The isolated recombinant polypeptide of claim 55, wherein the polypeptide comprises ~~an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids having an aligned contiguous segment from amino acid positions 1-47 or amino acid positions 104-276 of SEQ ID NO:2~~ an immunogenic fragment of at least 57 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject as a conjugate with a suitable carrier or in a composition which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

59. (Previously Presented) An isolated recombinant fusion protein comprising the isolated recombinant polypeptide of claim 55.

60. (**Currently Amended**) ~~An~~ The isolated recombinant fusion protein comprising the isolated recombinant polypeptide of claim 56 55, wherein the polypeptide comprises the amino acid sequence SEQ ID NO:2.

61. (**Currently Amended**) ~~An~~ The isolated recombinant fusion protein comprising the polypeptide of claim 58 55, wherein the polypeptide comprises an immunogenic fragment of at least 57 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject as a conjugate with a suitable carrier or in a composition which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

62. (**Currently Amended**) An immunogenic composition comprising the isolated recombinant polypeptide of claim 55, and a pharmaceutically acceptable carrier.

63. (**Currently Amended**) An immunogenic composition comprising the isolated recombinant fusion protein of claim 59, and a pharmaceutically acceptable carrier.

64-67. (**Canceled**)

68. (**Currently Amended**) A method for inducing an ~~immune response~~ antibody in a mammal comprising ~~administration of administering~~ the isolated recombinant polypeptide of claim 55 to the mammal in an amount effective to induce an antibody.

69. (**New**) The immunogenic composition of claim 62, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

70. (**New**) The immunogenic composition of claim 62, wherein the polypeptide comprises an immunogenic fragment of at least 57 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject as a conjugate with a suitable carrier or in a composition which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

71. (**New**) The immunogenic composition of claim 63, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

72. (**New**) The immunogenic composition of claim 63, wherein the polypeptide comprises an immunogenic fragment of at least 57 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject as a conjugate with a suitable carrier or in a composition which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

73. (**New**) The immunogenic composition of claim 62, further comprising at least one other *Moraxella catarrhalis* antigen other than a polypeptide comprising SEQ ID NO:2.

74. (**New**) The immunogenic composition of claim 63, further comprising at least one other *Moraxella catarrhalis* antigen other than a polypeptide comprising SEQ ID NO:2.